Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMO 2055

Drug Profile

IMO 2055

Alternative Names: EMD 1201081; HYB-2055; IMO-2055; IMOxine; TLR9 immunomodulator

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Idera Pharmaceuticals
  • Developer Aceragen; Merck KGaA
  • Class Antineoplastics; Oligonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Colorectal cancer; Head and neck cancer; Non-small cell lung cancer

Highest Development Phases

  • Suspended Colorectal cancer; Non-small cell lung cancer
  • Discontinued Asthma; Cancer; Head and neck cancer; Renal cell carcinoma

Most Recent Events

  • 17 Jan 2023 Idera Pharmaceuticals is now called Aceragen
  • 15 Apr 2021 Discontinued - Phase-II for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in United Kingdom, United Kingdom, Slovakia, Poland, Hungary, France, Czech Republic, Belgium, USA (SC)
  • 15 Apr 2021 Discontinued - Preclinical for Cancer in USA (Intratumoural)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top